ClinicalTrials.gg
RecruitingNCT06715540Updated Dec 16, 2024

Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

A Phase 1 interventional study of BCD-261, dose 1 and BCD-261, dose 2 in Healthy, sponsored by Biocad. Recruiting at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Biocad · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Mar 2024, registered Nov 2024).
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Colitis, Ulcerative with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Russian Federation.

Planned enrollment
65th of 70
48 · median 284
Started
2024
the only one that year
Phase 1
Only one
of the 73
Registered
73rd of 73
by date

Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, this one is the 65th largest by planned enrollment of the 70 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 73rd registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 73 studies in Colitis, Ulcerative with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Colitis, Ulcerative with a site in Russian Federation, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses to healthy male subjects aged from 18 to 45 years old.

The study consists of the first stage (dose escalation) and the second stage (dose expansion).

Read the detailed description

The study is conducted in 2 stages. During the Stage 1 of the study, dose escalation is performed in several cohorts to assess the effects of dose-limiting toxicity (DLT), the maximum tolerated dose of BCD-261.

During the dose escalation one subject ("sentinel volunteer") will be included in cohort 1. Starting from the 2nd cohort and up to the 6th cohort, the study is planned within a classic "3+3" design.

Based on the results of the analysis of the Stage 1 data, including the assessment of safety, pharmacodynamics, pharmacokinetics, immunogenicity of BCD-261, a decision will be made on the possibility of switching to the Stage 2 of the study (dose expansion).

DLT events will be monitored for 7 days after BCD-261 injection (during Stage 1), and may include any of CTCAE 5.0 grade ≥3 adverse events that are at least possibly related to the study drug.

During the Stage 2 an extended study of the safety, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 at two pre-selected proposed therapeutic doses, is carried out with the inclusion of several additional cohorts of healthy caucasians and asians.

03

Conditions studied

  • Healthy

Keywords

  • anti-TL1A
  • anti-TNF-like ligand 1A
  • Ulcerative Colitis
  • Inflammatory Bowel Disease
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed to participate in the study.
  2. For cohorts 1-8: Male subjects aged 18 to 45 years at the time of signing the ICF. For cohorts 9-10: Asian male subjects aged 18 to 45 years inclusive at the time of signing the ICF.
  3. The ability of the subject to follow the Protocol procedures, in the Investigator's opinion.
  4. A diagnosis of "healthy", established according to standard clinical, laboratory, and instrumental methods of examination carried out at screening, according to the assessment of the Investigator, as well as historical data (absence of acute and chronic diseases of the respiratory, cardiovascular, nervous systems, gastrointestinal tract, impaired liver or kidney function).
  5. Hemodynamic parameters within the normal range: systolic blood pressure (SBP) ranging 100 to 130 mmHg, diastolic (DBP) ranging 60 to 90 mmHg, pulse ranging 60 to 90 bpm at screening.
  6. Willingness of the subjects and their female partners of to use reliable methods from the moment of signing the ICF, throughout the main study period, and up to Day 57 inclusive. This requirement does not apply to participants who have undergone surgical sterilization.
  7. Willingness of subjects with to refrain from donating sperm, starting from the moment of signing the ICF, throughout the main study period until Day 57 inclusive.
  8. Willingness to refrain from participating in any other clinical trials, starting from the moment of signing the ICF and throughout the study.
  9. Willingness to refrain from vaccination with any vaccines during the period from the moment of signing the ICF until Day 127 of the study inclusive.

Exclusion criteria

Exclusion Criteria:

  1. Any medical or social condition that, in the opinion of the Investigator, prevents participation in this study.
  2. Any confirmed or suspected or immunodeficiency condition.
  3. Any acute infectious and non-infectious diseases, including the period of convalescence, within 4 weeks from the moment of clinical recovery to signing the ICF, as well as during screening.
  4. Diagnosis of infectious mononucleosis (documented or reported by the subject) within 2 months before signing the ICF and during screening.
  5. Vaccination with within 8 weeks and with any other vaccines within 4 weeks prior to signing the ICF and during screening.
  6. A history of allergies and signs of other significant adverse reactions after the administration of any medicinal products.
  7. to the components of BCD-261.
  8. (BMI) outside the normal range (18.0 to 30.0 kg/m2).
  9. Results of standard laboratory and instrumental tests outside the normal ranges adopted at the study site.
  10. Positive results of screening tests for , and C, tuberculosis.
  11. Repeated positive urine drug test, repeated positive saliva alcohol test at screening.
  12. Impossibility of venipuncture for blood sampling (e.g., due to skin diseases at the sites of venipuncture).
  13. Administration and use of the following drugs:

    • Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins, and dietary supplements, within less than 14 calendar days prior to estimated date of ID assignment.
    • A history of using anti-TL1A monoclonal antibodies.
    • Taking medications, including over-the-counter drugs, that have a pronounced effect on hemodynamics and liver function (barbiturates, omeprazole, cimetidine, etc.), within less than 30 days before the estimated date of ID assignment.
    • Taking drugs that affect the immune status (cytokines and their inducers, , etc.) within less than 60 days before the estimated date of ID assignment.
  14. Smoking of more than 10 cigarettes a day.
  15. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 20 mL of spirits) or a history of alcoholism, drug addiction or drug abuse.
  16. Surgical interventions performed less than within 90 days before the signing of the ICF.
  17. Donation of 450 mL or more of blood or plasma within 60 days prior to signing the ICF.
  18. Participation in any clinical study of medicinal products within 90 days before signing the ICF; previous participation in the same study with the exception of subjects who withdrew before the administration of the product.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Subjects in Cohort 1 will receive BCD-261 at a dose 1 during the Stage 1. Depending on the DLT, the cohort may include 1 to 3 subjects.

    Drug: BCD-261, dose 1

  • Experimental
    Cohort 2

    Subjects in Cohort 2 will receive BCD-261 at a dose 2 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.

    Drug: BCD-261, dose 2

  • Experimental
    Cohort 3

    Subjects in Cohort 3 will receive BCD-261 at a dose 3 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.

    Drug: BCD-261, dose 3

  • Experimental
    Cohort 4

    Subjects in Cohort 4 will receive BCD-261 at a dose 4 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.

    Drug: BCD-261, dose 4

  • Experimental
    Cohort 5

    Subjects in Cohort 5 will receive BCD-261 at a dose 5 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.

    Drug: BCD-261, dose 5

  • Experimental
    Cohort 6

    Subjects in Cohort 6 will receive BCD-261 at a dose 6 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.

    Drug: BCD-261, dose 6

  • Experimental
    Cohort 7

    Subjects in Cohort 7 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 7 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in vials.

    Drug: BCD-261, pre-specified therapeautic dose X

  • Experimental
    Cohort 8

    Subjects in Cohort 8 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 8 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.

    Drug: BCD-261, pre-specified therapeautic dose X

  • Experimental
    Cohort 9

    Subjects in Cohort 9 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 9 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.

    Drug: BCD-261, pre-specified therapeautic dose X

  • Experimental
    Cohort 10

    Subjects in Cohort 10 will receive BCD-261 at a pre-specified proposed therapeautic dose Y during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 10 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.

    Drug: BCD-261, pre-specified therapeautic dose Y

Interventions

  • DrugBCD-261, dose 1

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, dose 2

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, dose 3

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, dose 4

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, dose 5

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, dose 6

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, pre-specified therapeautic dose X

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

    Also known as: anti-TL1A

  • DrugBCD-261, pre-specified therapeautic dose X

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

    Also known as: anti-TL1A

  • DrugBCD-261, pre-specified therapeautic dose Y

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

    Also known as: anti-TL1A

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with adverse reactions

    Time frame: 127 days

  2. Proportion of subjects with serious adverse reactions

    Time frame: 127 days

  3. Proportion of subjects with CTCAE 5.0 grade 3 or higher adverse reactions

    Time frame: 127 days

  4. Proportion of subjects who prematurely withdrew from the study due to adverse reactions

    Time frame: 127 days

Other outcomes

  1. Cmax (Maximum concentration)

    Time frame: 127 days

  2. Tmax (Time of maximum observed concentration)

    Time frame: 127 days

  3. T1/2 (Elimination half-life period)

    Time frame: 127 days

  4. Kel (Elimination rate constant)

    Time frame: 127 days

  5. Cl (Clearance)

    Time frame: 127 days

  6. Vd (Volume of distribution)

    Time frame: 127 days

  7. Cmin (Minimum observed concentration)

    Time frame: 127 days

  8. AUC(0-1344) (Area under curve from 0 to 1344 hours)

    Time frame: 57 days

  9. AUC(0-inf) (Area under curve from 0 to infinity)

    Time frame: 127 days

07

Study locations

1 of 1 sites recruiting
  • "Meditsinskiy teсhnologiy Maly"
    St. Petersburg, 197198, Russian Federation
    Recruiting
    • Ivan S Sardaryan, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2025, 11 months after the start.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 11 months is close to that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2024
First posted
Dec 4, 2024
StartActual
Mar 29, 2024
Primary completionEst.
Feb 2025
CompletionEst.
Dec 2025
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715540
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Mar 29, 2024
Primary completion
Feb 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 16, 2024

Study contacts

Yulia E Tsarikhina, MD
Contact
tsarikhina@biocad.ru
+7 (981) 698 14 22
Arina V Zinkina-Orikhan, PhD
study director · Director of Clinical Development Department, BIOCAD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion